Wells Fargo lowered the firm’s price target on Rapt Therapeutics to $32 from $42 and keeps an Overweight rating on the shares. Following Rapt Therapeutics’ update on zelnecirnon and a review of precedent liver failure cases with other drugs, the firm notes a range of possible outcomes and would await additional info to better assess the relatedness of the SAE to zelnecirnon and the path forward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RAPT:
- RAPT Therapeutics Hit by FDA Clinical Trial Hold
- RAPT Therapeutics (NASDAQ:RAPT) Crashes 60% after FDA Places Clinical Hold
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
- Rapt Therapeutics initiated with an Outperform at Evercore ISI
